RayKnowChina Research Map
Shortlist

RecruitingLymphomaEarly phase 1

Registered title, quoted from ClinicalTrials.gov

Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)First Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06633341, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 1. According to the 2016 WHO classification of lymphocyte tumors, histologically confirmed CD5-positive T-cell non-Hodgkin lymphoma (T-NHL),

    Inclusion criterion 1

  2. 6. Received anti-tumor therapy before infusion, should meet the following any one should be ruled out:

    Exclusion criterion 6

    received within 72 hours of small molecule targeted therapy;

    Exclusion criterion 8

    2 weeks received systemic chemotherapy except (pretreatment);

    Exclusion criterion 9

  3. 8. ECOG 0-2;

    Inclusion criterion 11

  4. 4. Total bilirubin ≤51 (mol/L), Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) ≤ 3 times the upper limit of the normal range, creatinine ≤176.8 (mol/L);

    Inclusion criterion 7

  5. 3. Active infection of hepatitis B virus, C virus or hepatitis E virus;

    Exclusion criterion 3

  6. 9. Pregnant/lactating women, or male or female patients who have fertility and are willing to take effective contraceptive measures at least 6 months after the last cell infusion during the study period;

    Inclusion criterion 12

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06633341, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 1. According to the 2016 WHO classification of lymphocyte tumors, histologically confirmed CD5-positive T-cell non-Hodgkin lymphoma (T-NHL),

R/R T-NHL(meets one of the following conditions) :

  • Subjects did not go into remission or relapse after receiving second-line or more chemotherapy regiments;
  • Primary drug resistance;
  • Relapse after autologous hematopoietic stem cell transplantation;
  • 2.CD5 expression rate was >90%;
  • 3. According to Lugano 2014, there should be at least one evaluable tumor lesion;
  • 4. Total bilirubin ≤51 (mol/L), Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) ≤ 3 times the upper limit of the normal range, creatinine ≤176.8 (mol/L);
  • 5. Echocardiography showed left ventricular ejection fraction (LVEF) ≥50%;
  • 6. Refers to the pulse oxygen saturation 92% or higher oxygen (state);
  • 7. Estimated life expectancy of minimum of 12 weeks;
  • 8. ECOG 0-2;
  • 9. Pregnant/lactating women, or male or female patients who have fertility and are willing to take effective contraceptive measures at least 6 months after the last cell infusion during the study period;
  • 10. Those who voluntarily participated in this trial and provided informed consent;

Exclusion Criteria:

  • 1. History of epilepsy or other central nervous system disorders;
  • 2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
  • 3. Active infection of hepatitis B virus, C virus or hepatitis E virus;
  • 4. Active infected persons who are not cured;
  • 5. Before using any gene therapy products;
  • 6. Received anti-tumor therapy before infusion, should meet the following any one should be ruled out:
  • treated with systemic corticosteroids therapy within 72 hours (except glucocorticoid physiological replacement therapy, such as prednisone < 10 mg/d or an equivalent dose of the drug);
  • received within 72 hours of small molecule targeted therapy;
  • 2 weeks received systemic chemotherapy except (pretreatment);
  • four weeks received radiotherapy;
  • 7. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal;
  • 8. Any unsuitable to participate in this trial judged by the investigator;
  • 9. Any situation that researchers believe may increase the risk to the subjects or interfere with the trial results.

Quoted from ClinicalTrials.gov, NCT06633341, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06633341, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06633341